- Home
- LOMA vs MNKD Comparison
LOMA vs MNKD Comparison
Compare LOMA & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOMA
- MNKD
- Stock Information
- Founded
- LOMA 1926
- MNKD 1991
- Country
- LOMA Argentina
- MNKD United States
- Employees
- LOMA N/A
- MNKD N/A
- Industry
- LOMA Building Materials
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- LOMA Industrials
- MNKD Health Care
- Exchange
- LOMA Nasdaq
- MNKD Nasdaq
- Market Cap
- LOMA 1.3B
- MNKD 1.2B
- IPO Year
- LOMA 2017
- MNKD 2004
- Fundamental
- Price
- LOMA $7.56
- MNKD $5.50
- Analyst Decision
- LOMA Strong Buy
- MNKD Strong Buy
- Analyst Count
- LOMA 2
- MNKD 5
- Target Price
- LOMA $15.00
- MNKD $10.80
- AVG Volume (30 Days)
- LOMA 716.7K
- MNKD 5.5M
- Earning Date
- LOMA 11-05-2025
- MNKD 11-06-2025
- Dividend Yield
- LOMA N/A
- MNKD N/A
- EPS Growth
- LOMA N/A
- MNKD 149.32
- EPS
- LOMA 0.37
- MNKD 0.11
- Revenue
- LOMA $559,741,122.00
- MNKD $301,736,000.00
- Revenue This Year
- LOMA $22.92
- MNKD $14.52
- Revenue Next Year
- LOMA $25.84
- MNKD $12.81
- P/E Ratio
- LOMA $21.63
- MNKD $50.09
- Revenue Growth
- LOMA N/A
- MNKD 21.48
- 52 Week Low
- LOMA $7.20
- MNKD $3.38
- 52 Week High
- LOMA $14.17
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- LOMA 18.12
- MNKD 68.09
- Support Level
- LOMA $7.71
- MNKD $5.36
- Resistance Level
- LOMA $8.34
- MNKD $5.68
- Average True Range (ATR)
- LOMA 0.44
- MNKD 0.30
- MACD
- LOMA -0.15
- MNKD 0.07
- Stochastic Oscillator
- LOMA 2.22
- MNKD 71.11
About LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.